Amarin Corp. plc, of Dublin, recognized $47.1 million in U.S. net product revenue from triglyceride-lowering Vascepa (icosapent ethyl) sales in the third quarter, compared to $32.4 million in the same period last year, an increase of 45 percent. The company increased normalized prescriptions for Vascepa by 44 percent compared to the third quarter of 2016. Net product revenue for the nine months ended Sept. 30, 2017, and 2016 was $126.3 million and $90.6 million, respectively, mainly attributed to increased Vascepa prescriptions, Amarin said.
Intercept Pharmaceuticals Inc., of New York, recorded $40.9 million in worldwide net sales of Ocaliva (obeticholic acid), including a change in estimate related to deferred revenue with a net effect of a one-time increase of $4.1 million in net revenue for the third quarter. Net U.S. Ocaliva sales were $36.2 million, which included $3.7 million for the change in estimate related to deferred revenue. Net ex-U.S. international Ocaliva sales were $4.7 million, which included $400,000 for the change in estimate related to deferred revenue. Ocaliva was approved by the FDA in May 2016 for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as a monotherapy in adults unable to tolerate UDCA.